Ceftizoxime: Difference between revisions

Jump to navigation Jump to search
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
mNo edit summary
Line 1: Line 1:
{{refimprove|date=April 2013}}
{{Drugbox
{{Drugbox
| IUPAC_name       = (6''R'',7''R'')-7-{[(2''Z'')-2-(2-amino-1,3-thiazol-4-yl)-<br>2-methoxyiminoacetyl]amino]-8-oxo-5-thia-<br>1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic&nbsp;acid
| IUPAC_name = (6''R'',7''R'')-7-{[(2''Z'')-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| image             = ceftizoxime.png
| image = ceftizoxime.png
| CAS_number        =
 
| ATC_prefix        = J01
<!--Clinical data-->
| ATC_suffix        = DD07
| tradename = Cefizox
| PubChem          = 6533629
| Drugs.com = {{drugs.com|CDI|ceftizoxime}}
| DrugBank          =
| MedlinePlus = a684043
| C=13|H=13|N=5|O=5|S=2
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| molecular_weight  = 383.405 g/mol
| pregnancy_US = <!-- A / B            / C / D / X -->
| bioavailability  =
| pregnancy_category =   
| protein_bound    =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| metabolism        =
| legal_CA = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| elimination_half-life =
| legal_UK = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| excretion        =  
| legal_US = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| pregnancy_AU     = <!-- A / B1 / B2 / B3 / C / D / X -->
| legal_status =
| pregnancy_US     = <!-- A / B            / C / D / X -->
| routes_of_administration =
| pregnancy_category=   
 
| legal_AU         = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
<!--Pharmacokinetic data-->
| legal_CA         = <!--            / Schedule I, II, III, IV, V, VI, VII, VIII -->
| bioavailability = 
| legal_UK         = <!-- GSL        / P      / POM / CD / Class A, B, C -->
| protein_bound = 
| legal_US         = <!-- OTC                  / Rx-only  / Schedule I, II, III, IV, V -->
| metabolism = 
| legal_status     =  
| elimination_half-life = 
| routes_of_administration =  
| excretion =
 
<!--Identifiers-->
| CAS_number = 68401-81-0
| CAS_supplemental = {{CAS|68401-82-1}}
| ATC_prefix = J01
| ATC_suffix = DD07
| PubChem = 6533629
| DrugBank = 
| ChemSpiderID = 5018818
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = C43C467DPE
| KEGG = D07658
| ChEMBL = 528
 
<!--Chemical data-->
| C=13 | H=13 | N=5 | O=5 | S=2
| molecular_weight = 383.405 g/mol
}}
}}
{{SI}}
__NOTOC__
{{CMG}}
 
==Overview==
Ceftizoxime is a third-generation [[cephalosporin]] available for [[parenteral administration]].


Unlike other 3rd generation cephalosporins, in ceftizoxime the whole C-3 side chain has been removed to prevent [[enzymatic hydrolysis|deactivation]] by [[hydrolytic enzyme]]s.
It rather resembles [[cefotaxime]] in its properties, but is not subjected to [[hepatic metabolism|metabolism]].


'''Ceftizoxime''' is a [[cephalosporin]].
==Category==


==US Brand Names==


==FDA Package Insert==
'''  [[XXXXX description|Description]]'''
'''| [[XXXXX clinical pharmacology|Clinical Pharmacology]]'''
'''| [[XXXXX microbiology|Microbiology]]'''
'''| [[XXXXX indications and usage|Indications and Usage]]'''
'''| [[XXXXX contraindications|Contraindications]]'''
'''| [[XXXXX warnings and precautions|Warnings and Precautions]]'''
'''| [[XXXXX adverse reactions|Adverse Reactions]]'''
'''| [[XXXXX overdosage|Overdosage]]'''
'''| [[XXXXX clinical studies|Clinical Studies]]'''
'''| [[XXXXX dosage and administration|Dosage and Administration]]'''
'''| [[XXXXX compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]'''
'''| [[XXXXX directions for use|Directions For Use]]'''
'''| [[XXXXX how supplied|How Supplied]]'''
'''| [[XXXXX labels and packages|Labels and Packages]]'''


{{CephalosporinAntiBiotics}}
==Mechanism of Action==


[[Category:Cephalosporin antibiotics]]
==References==
{{Reflist|2}}


{{WikiDoc Help Menu}}
[[Category:Antibiotics]]
{{WS}}
[[Category:Wikinfect]]

Revision as of 03:34, 31 December 2013

{{Drugbox | IUPAC_name = (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | image = ceftizoxime.png

| tradename = Cefizox | Drugs.com = Consumer Drug Information | MedlinePlus = a684043 | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number = 68401-81-0 | CAS_supplemental = 68401-82-1 | ATC_prefix = J01 | ATC_suffix = DD07 | PubChem = 6533629 | DrugBank = | ChemSpiderID = 5018818 | UNII_Ref =  ☑Y | UNII = C43C467DPE | KEGG = D07658 | ChEMBL = 528

| C=13 | H=13 | N=5 | O=5 | S=2 | molecular_weight = 383.405 g/mol }}

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ceftizoxime is a third-generation cephalosporin available for parenteral administration.

Unlike other 3rd generation cephalosporins, in ceftizoxime the whole C-3 side chain has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subjected to metabolism.

Category

US Brand Names

FDA Package Insert

Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages

Mechanism of Action

References